63 results about "Tumour targeting" patented technology

The invention relates to a bio-assay reagent for early diagnosis of tumor and a prodrug for the targeted therapy of tumor, in particular to a targeted tracing noble metal fluorescence probe and an anti-tumor prodrug. Through experiment, the synthesized probe does not have cytotoxicity and is safe and effective, can realize the level imaging of cells and the imaging of in-vivo tumor, and has good prospect when used as the targeted fluorescence probe or the prodrug.

The invention belongs to the field of medicine preparation and particularly relates to a docetaxel solid lipid nanoparticle and a preparation method thereof. The docetaxel solid lipid nanoparticle consists of an effective curative dose of docetaxel, solid lipid materials, liquid lipid materials, an emulsifying agent, additives, long-circulating auxiliary materials and water for injection. The docetaxel solid lipid nanoparticle provided by the invention has the characteristics of stable docetaxel structure, phagocytosis prevention of an in-vivo reticuloendothelial system and active tumor targeting, and can be stably stored.

The invention can be summarized as follows. According to the present invention there is provided an attenuated, tumour-targeting bacterium comprising a heterologous nucleotide sequence encoding a protein permitting the accumulation of a radionuclide within the bacterium. The heterologous nucleotide sequence may encode a sodium iodide symporter protein. The invention also relates to the use of such bacteria and methods of treating diseases using the bacteria of the present invention.

The invention relates to a polypeptide with tumor-targeting performance and a preparation method. The structure of the aminophenol sequence of the polypeptide is CASPSGALRSC or CFPVPGHDLVC or CFSVPGHDIVC or CTPMSLSLSEC or CYTYPLGWHIC. The pC89 phage peptide library expressing protein polypeptides with different sequences of 108 and human breast cancer cell lines MDA-MB-231 are repetitively cocultured for a few times; filtration can penetrate cell membrane to enter into the phages expressing specific polypeptide in cytolymph and / or karyon, and phages are amplified in vitro in order to carry out DNA sequencing and deduce an exogenous amino acid sequence inserted in the phages; the filtered specific polypeptide phages, other human tumor cells and normal cells are cocultured in vitro, and the tumor cell specificity of the polypeptide phages is tested; according to the testing results of polypeptide sequence and cell specificity, the polypeptide with tumor targeting is artifically synthesized. The invention as a specificity carrier of the mammary cancer-targeting genetic therapy has potential clinic application value. The invention also provides a strong technical support for the filtration of affinity specificity polypeptide of other types of malignant tumor cell strains. Moreover, the polypeptide only contains nine to eleven amino acid residues, so the polypeptide can be easily synthesized, the change of spacial position is relatively less, the quality control of the polypeptide is easy, and use is convenient.

The invention discloses a galactose-containing platinum complex for tumor targeted therapy and a preparation method thereof; the complex is shown in formula (I); and experiment demonstrates that the complex of the invention and medicaments prepared by the complex of the invention have high water solubility, have tumor target effect, and is convenient for clinical application.

The invention provides a self-assembly hyaluronic acid-indissolvable prodrug-coated active medicine-encapsulated liposome nano administration system and a preparation method thereof, which belong to the field of a medicinal preparation. The nano administration system comprises the following components: an active medicine, a hyaluronic acid-indissolvable prodrug and liposome. The self-assembly hyaluronic acid-indissolvable prodrug-coated active medicine-encapsulated liposome nano administration system having the nano preparation property can effectively and rapidly deliver the active medicine and the prodrug to tumor part through EPR effect, and reduces the drug amount in normal tissue; based on active targeting of the self-assembly hyaluronic acid-indissolvable prodrug-coated active medicine-encapsulated liposome nano administration system, after the active medicine and the prodrug arrive near to the tumor part, CD44 acceptor combination can be highly expressed through hyaluronic acid and tumor cells, the medicine is mediated into the cells, the drug amount in normal tissue is enhanced, and the antineoplastic capability of the medicine is obviously increased. The administration system is characterized in that two medicines having synergism are simultaneously delivered on a same carrier, has consistency of space and time, increases the tumour targeting, and increases the medicine curative effect.

A transgenic carrier with deal targets (fibroblast growth factor receptor and integrant) is composed of the polypeptide CR16 specifically linked with alkaline fibroblast growth factor receptor, the polypeptide CP9 specifically linked with integrant, and the transgenic non-virus carrier system of CR16 / CP9 / cationic polymer PEI / exogenous DNA. Said carrier can effectively introduce the exogenous DNA to the tumor cell line and tumor tissue with high expression of FGFRs, so suppressing the growth of tumor. It can be used to preparation of the medicine for treating tumor and other diseases.

The present invention relates to a bladder tumor-targeting peptide and use thereof. More particularly, the present invention relates to a bladder tumor-targeting peptide having an amino acid sequence represented by SEQ ID NO: 7 and use thereof. The peptide according to the present invention is capable of specific binding to bladder tumor cells in vivo and in vitro. The peptide according to the present invention or an antibody thereof is useful for a marker for the diagnosis of bladder tumors, and for a drug carrier targeting bladder tumor.

The invention discloses an anti-human DLL4 monoclonal antibody and aplysiatoxin derivative MMAE conjugate, which relates to the technical field of biological pharmacy. The invention is characterized by comprising a preparation method of the conjugate of micromolecule toxin aplysiatoxin derivative MMAE and the anti-human DLL4 monoclonal antibody MMG201 as well as a purpose thereof. The method employs anti-human DLL4 monoclonal antibody MMG201 and selects a vcMMAE joint and a pharmaceutical composition, a phosphine reducing agent tricarboxyethyl phosphine TCEP is used for partially reducing the antibody MMG201 during a coupling technology, then the antibody MMG201 is subjected to coupling with vcMMAE and is subjected to conjugate purifying, through optimization of the process, a novel anti-human DLL4 monoclonal antibody medical conjugate MvM03 is prepared, the novel anti-human DLL4 monoclonal antibody medical conjugate MvM03 has the beneficial effect that the tumour targeting of toxin molecule MMAE is promoted, the poisoning effect on body normal cell is reduced, and the good treatment effect can be achieved.

A nanoparticulate composition is disclosed for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation / modified polycation or the polyanion / modified polyanion, or both; (ii) an active compound selected from the group of epirubicin and its pharmaceutically acceptable salts, especially hydrochloride; and optionally (iii) at least one complexing agent, metal ion and stabilizer / formulating agent. The invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention.

The invention relates to a polypeptide capable of specific tumor-binding. The amino acid sequence of the polypeptide is shown as SEQ ID No.1. According to the invention, phages specifically binding with lung cancer are obtained by means of a phage display in vivo screening method to determine sequence in order to synthesize the specific binding polypeptide. The polypeptide can achieve excellent in vitro binding with a plurality of tumor cells subsequent to the conjunction with poly(amidoamine) dendrimer nano material. As verified by in vitro experiments, the target polypeptide has a very hightumor targeting effect and can be widely used as a targeting agent in diagnostic imaging and targeted treatment of tumors.

The invention relates to a three-function peptide-modified gene carrier as well as a preparation method and application thereof, particularly provides a polypeptide with the functions of tumour targeting, membrane penetrating boosting and core positioning, a gene carrier formed by coupling the polypeptide and amphiphilic chitosan-modified polyethyleneimine, a preparation method of the gene carrier, a compound prepared from the gene carrier and DNA, and the application of the polypeptide with the three functions and the gene carrier in the preparation of a medicine for gene treatment. The three-function peptide-modified gene carrier is high in internal transfection efficiency, low in cytotoxicity, strong in targeting performance, and has wide clinical application prospect.

The invention provides chimeric polypeptide of chrotoplast growth inhibitors in human vessels. The chimeric polypeptide is RGD-VEGI-192A chimeric recombinant protein formed by connecting the growth inhibitor VEGI-192A and RGD-4C. The preparation method for the chimeric polypeptide comprises steps that nucleotide sequences shown in the SEQ IDNO:1 construct expression vector and induces the expression in host cells. The chimeric polypeptide is a new angiogenesis antagonist, can be applied to the targeted antitumor and has potential treatment valve in angiogenesis diseases such as tumor and the like. In addition, the chimeric polypeptide enriches the application form of the VEGI-192A in the tumor treatment and provides new idea for the targeted treatment of the tumor and lays foundations for the development of the RGD-VEGI-192A chimeric polypeptide as a more effective clinical drug.

The invention relates to a series of brand-new micromolecular targeted diagnosis reagents and photodynamic therapy (PDT) medicines for tumour. In the brand-new micromolecular targeted diagnosis reagents for tumour and the PDT medicines disclosed by the invention, tumour-targeting carrier molecules are connected with a photosensitizer via connection chemical bonds, thereby achieving a purpose of directionally conveying photosensitive medicines to cancer pathological cells and tissues. The compounds can be used for cancer diagnosis and location, observation pharmacokinetic and early evaluation for the effect of PDT after being combined with imaging isotope by the characteristic that Ce6 can be in complexation with metal ions.

The invention discloses a bionic nano-carrier and an application thereof in preparation of brain glioma treatment medicines, and belongs to the technical field of medicines. The bionic nano-carrier comprises a long-circulating liposome and a hybrid cell membrane; the long-circulating liposome serves as an inner core, the hybrid cell membrane serves as a shell, and the long-circulating liposome is coated with the hybrid cell membrane; and the hybrid cell membrane is formed by mixing an immune cell membrane and a tumor cell membrane. According to the nano-carrier disclosed by the invention, the long-circulating liposome is taken as a core, the core is coated with a hybrid cell membrane of immune cells and tumor cells, the nano-carrier moves and passes through a blood-brain barrier through the interaction of surface protein of the immune cells and receptors on brain endothelial cells, and meanwhile, the enhanced tumor targeting capability is realized through homologous targeting and homing effects, targeted treatment of brain glioma is achieved, and the chemotherapy effect is improved.

The present invention relates to tumour targeting ablation planning.As a facilitated and improved image-based planning method, a method (100) for tumour targeting ablation planning is provided: At least one segmented tumour in a 3D data set (112) to be treated in an ablation procedure is provided (110). A contour (116) of the segmented tumour is generated and displayed (114). A predetermined ablation profile (120) to overlap with at least a part of the at least one segmented tumour is provided and displayed (118). An overlapping region (124) is identified (122) and a predetermined safety factor (128) is applied (126) to at least a part of the overlapping region to generate (130) a modified overlapping region (132). Parts of the overlapping region arranged outside the modified overlapping region are then determined (134) as critical overlapping portions (136). The critical overlapping portions are displayed (138) in relation with the contour and the ablation profile as virtual planning ablation result (140).

The invention discloses an escherichia coli Nissle 1917 anti-tumor targeted engineering bacterial strain as well as a construction method and application thereof. The escherichia coli Nissle 1917 anti-tumor targeted engineering bacterial strain is collected in China Center For Type Culture Collection on June 26, 2018, with the culture collection number of CCTCC NO: M 2018403; the classification name thereof is escherichia coli EcN (Tum 5-p53), and the Latin scientific name thereof is Escherichia coli Nissle (Tum 5-p53). The constructed escherichia coli EcN (Tum 5-p53) contains an anti-tumor hypoxic expression vector pET28a-Pvhb-SUMO-Tum 5-MMP-p53, can efficiently express bifunctional protein Tum 5-p53, can transmit an antiangiogenic factor Tum-5 and tumor suppressor protein p53 to a solidtumor, and plays a good anti-tumor therapeutic effect. The tumor inhibiting rate of the anti-tumor targeted engineering bacterial strain on a human liver cancer SMMC-7721 nude mouse is as high as 69.47%.

The invention relates to the field of gene detection and bioinformatics, and discloses a method for mining complex disease markers based on transcriptome data, exon group / genome data and clinical phenotypes. The invention designs a set of calculation method for constructing a complex disease state evaluation model by integrating high-throughput sequencing data and clinical phenotypes, the calculation method is applied to targeted medication of colorectal cancer, pancreatic ductal cancer and pancreas ductal cancer, biomarkers related to diseases are screened respectively, and the correspondingdisease state evaluation model is formed. The marker considering both accuracy and mechanism interpretability is constructed through the method and can be used for prognosis evaluation of complex diseases, treatment effect prediction, treatment scheme assistant decision making and the like.

The invention relates to a preparation method of paclitaxel nano micelle, which comprises the following steps of: taking a block copolymer of polyether and polyester as a medicine supplementary material and paclitaxel as a medicine; and preparing the paclitaxel nano micelle by rotating an evaporation solvent, wherein the medicine supplementary material is prepared through body ring-opening polymerization, and the terminal hydroxyl group of the copolymer is modified into carboxylate so as to increase the stability of the micelle. According to the micelle disclosed by the invention, during the preparation process, no stabilizing agent is added, and the obtained medicine-carrying micelle can stably exist for over 48h under the body fluid environment, is a paclitaxel nano sustained-release carrier with a good application prospect, and has the characteristics of stability and tumour targeted effect.

The invention discloses a peptide - cisplatin conjugate which is prepared by taking a peptide containing 12 amino acids as a carrier and coupling the pipetide with anticancer drug cisplatin, and the invention makes initial research on the pharmacological properties of the peptide - cisplatin conjugate. Cisplatin is widely applied to traditional cancer treatment, but the advantages of great toxic and side effect and the like thereof restrict the application thereof in the treatment. Therefore, to reduce the toxic and side effect of cisplatin is the key to improve the cisplatin medicine. The peptide - cisplatin conjugate obtained by the coupling of peptide and the cisplatin through chemical reaction has small molecular weight when being used for preparing anti-tumor disease medicine, has noantigenicity, does not cause allergic reaction, helps the medicine to display tumor targeting property, takes envoplakin, CD63 and other antigen as the targets, kills tumors with high efficiency, promotes the apoptosis of tumor cells and reduces the toxic and side effect.

The invention discloses a recombinant influenza virus rescue method and an application of the same in tumor therapy. The method for preparing recombinant viruses that express antibodies to anti-tumorprotein or contain coding genes of fusion protein includes that single-stranded coding genes, heavy-strained coding genes an / or light-stranded coding genes of anti-tumor protein antibodies are savedby viruses to obtain recombinant viruses with single-stranded, heavy-stranded and / or light-stranded coding genes of anti-tumor protein antibodies and other transforming growth factor receptor or extracellular domain coding genes of the receptor. The recombinant viruses expressing immune checkpoint suppress antibodies are designed; the heavy and light chains encoding immune checkpoint suppress antibodies are constructed in the HA region and NA region of PR8 viruses respectively, and the recombinant oncolytic influenza viruses are constructed to express anti-pd1 anti-pd-L1 antibodies. The oncolytic recombinant influenza viruses provided can target and kill tumor cells without obvious impact on normal host cells and can be used for targeted tumor therapy.

The invention, belonging to the field of biotechnology, relates to a brain tumor targeting gene delivery composite modified by low density lipoprotein receptor associated protein ligand polypeptide. The brain tumor targeting gene delivery composite has a dual targeting effect of BBB and glioma. Therapeutic genes can express and kill tumor cells in glioma cells, and can release gene product TRAIL protein into the environment outside the cells to combine with tumor cells by the means of cell paracrine after expressing in BCECs and then have a killing effect, thus aiming at the infiltrative growth characteristic of glioma in the brain, the brain tumor targeting gene delivery composite can kill the main glioma and simultaneously effectively inhibit the diffusion of scattered tumor cells.

The invention provides a tumor-targeted fluorescent probe, and application of the fluorescent probe in tumor NO detection, which belongs to the biotechnology field. The invention in particular relates to a fluorescent probe which can be targeted to a tumor tissue based on specificity. The fluorescent probe can form a complex with double-charge copper ions, and can be applied for the fluorescent imaging detection of the level of NO in the tumor. The fluorescent probe is the Top10 bacterial strain of colibacillus modified with N-(3-(2- phenyl imidazolyl)-4-hydroxy phenyl) maleimide. The fluorescent probe can be targeted to the tumor tissue quickly in a mammal body. In addition, the complex formed by the fluorescent probe and the double-charge copper ions can react with NO released in the tumor tissue, thus significantly improving the fluorescence intensity. In this way, the fluorescent probe can be used for the fluoroscopic detection of NO in the tumor tissue of a living body and the fluorescent imaging of the living body.

The invention belongs to the biomedicine technology field, in particular relates to a new nano-preparation of anthracene-ring medicine, such as adriamycin, etc. and a preparation method thereof. The preparation is composed of anthracene-ring medicine such as adriamycin, nucleic acid, and cationic compound. The specific preparation process is that the anthracene-ring medicine is compounded with the nucleic acid firstly, and then is compounded with the cationic compound to form nano-granule. The preparation reduces the physiological toxicity of anthracene-ring medicine without reducing the anti-cancer activity, has tumor targeting characteristic and can be prepared into tumor-treating medicine.

The invention relates to the field of medicinal biotechnology, particularly to an application of a new cancer suppressor gene FBP1 in the preparation for a medicine for diagnosing, preventing and treating tumour. The cancer suppressor gene is expressed with a low specificity in a tumour cell and a tumour tissue, and has a function of inhibiting the growth of the tumour cell; therefore, the tumours expressing the cancer suppressor gene with a low specificity are selected, and the expression of the cancer suppressor gene in the tumour cell is specifically recovered. A new method is provided for a tumour targeted therapy.

The invention discloses a sensitizer drug, a pharmaceutical composition and application. A sensitizer in the invention is a Pin1 inhibitor; the clinical effect of tumour targeting therapy is easily improved by inhibiting prolyl isomerase Pin1 and improving the sensibility of expression of BRCA1 breast cancer on a PARP inhibitor; in addition, the pharmaceutical composition of the Pin1 inhibitor andthe PARP inhibitor in the invention can be used for preparing a therapeutic drug targeting HR sensitive tumours, and can be used for treating BRCA1 wild type cancers; and furthermore, the pharmaceutical composition is good in security and low in toxicity.

The invention discloses a nanothermal seed material used for microwave tumour targeted thermal therapy. The nanothermal seed material used for the microwave tumour targeted thermal therapy is composed of the following components in percentage by weight: 40-75% of tin and manganese doped barium ferrite, 5-15% of magnesium oxide, 5-10% of titanium oxide and the balance of silicon oxide. The invention also discloses a preparation method of the nanothermal seed material. The preparation method of the nanothermal seed material comprises the following steps: firstly preparing tin and manganese doped barium ferrite nano powder, respectively weighing tin and manganese doped barium ferrite nano powder, magnesium oxide powder, titanium oxide powder and silicon oxide powder in percentage by weight according to a formula, fully dispersing by carrying out high-energy ball milling, then putting the fully dispersed powder into a graphite grinding tool, sintering in a hot pressing sintering furnace, mechanically pulverizing a composite material obtained after sintering, and refining to obtain nanoscale powder by utilizing high-energy ball milling. The nanothermal seed material has the characteristics of strong microwave heat effect, good biocompatibility and easiness for surface modification in a microwave frequency band used for tumour thermal therapy, and can be applied to microwave tumour targeted thermal therapy.